Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

International guidelines conditionally recommend long-term prophylaxis in patients with von Willebrand disease (VWD) and severe and frequent bleeding. As recombinant von Willebrand factor (rVWF; vonicog alfa) may reduce the frequency of treated spontaneous bleeding events (BEs), we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Leebeek, Frank W. G., Peyvandi, Flora, Escobar, Miguel, Tiede, Andreas, Castaman, Giancarlo, Wang, Michael, Wynn, Tung, Baptista, Jovanna, Wang, Yi, Zhang, Jingmei, Mellgård, Björn, Özen, Gülden
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283967/
https://www.ncbi.nlm.nih.gov/pubmed/35439298
http://dx.doi.org/10.1182/blood.2021014810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283967/
https://www.ncbi.nlm.nih.gov/pubmed/35439298
http://dx.doi.org/10.1182/blood.2021014810

Ejemplares similares